Feb 8th 2023 - Mar 22nd 2023
Whereas it’s own SVB and Signature Bank being audi... See more
$BBBY passing $1.44 again means there will be a ni... See more
The Motley Fool Stock Advisor has a track record that speaks for itself, with average recommendations that have returned over 542%*. Act now so you can start investing smarter, not harder.
*As of October 2023$79 is an introductory price for new members only. 60% discount based on the current list price of Stock Advisor of $199/year. Membership will renew annually at the then current list price.Feb 7th 2023 - Mar 21st 2023
$AVXL thanks yet again Bill.
Worth the risk with patience and not investing lif... See more
Whereas it’s own SVB and Signature Bank being audited by US KPMG was given clean bill of health !
$BBBY passing $1.44 again means there will be a nice run today and monday $EVIO (about to clear 1s) Do it quick.
Cheap, less regulations, Covid will pass and the rest of the markets are overvalued!
$GOTU This time Gotu will explode pass $2.
PCAOB recent audit has given Baba a clean bill of approval.
you people have no idea how undervalued this is, if Bill Gates is ready to loan me some money I got the greatest investment of all time.
The best part is, US markets are at session highs and $ is sinking on the day as markets expect Republicans to take both House and Senate.
Many USA Presidents are going to pass through WS while he will stay in charge over and over and over. .
Baba and BIDU fit the bill and can succeed!
$HKD buying more, too good of price to pass up
$HKD just wait buddy we will pass competition very fast in next week
..pick me up or pass me whenever 💸💸💸💸💸💸💸💸💸💸💸💸💸💸💸💸🤑🤑🤑
Hard to pass up this price !
$AVXL thanks yet again Bill.
Worth the risk with patience and not investing lifestyle or bill money.
But, after cognition tests the trial passed all endpoints!
THEN they said it hadnt passed any trials, well gee whiz now met BOTH secondary Endpoints. Newsflash.
Blarcamesine passed every endpoints. .
Key is we passed all endpoints with statically significant results!
Hahah .. passed easily!
Passed it all no problem!
After TLR, Anavex will be the owner of a first-in-class, patented, medically-proven, high-demand asset that merely needs to pass through the technicality of government approval to qualify it for mass marketing.
